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A new era in genomic medicine
Since the completion of the initial sequencing of the 
human genome [1,2] there has been more than a decade 
of refinement and optimization of whole genome 
sequencing [3,4]. In 2007, when it was still too expensive 
to sequence whole genomes in any large quantity, it was 
first demonstrated that one can capture and sequence the 
protein coding exons from individual human genomes 
[5,6]. This was followed by the first in-depth analysis of 
an ‘exome’, defined as ‘the set of exons in a genome’ [7]. 
The next year saw the sequencing of 12 human exomes 
[8], followed a year later by the use of exome sequencing 
to determine the genetic basis for cases of Bartter syn-
drome [9], Miller syndrome [10] and Kabuki syndrome 
[11]. By 2010, with the cost of sequencing plummeting 
due to the rapid development of newer and better 
technologies, the question arose concerning when and 
whether it would be better and more cost-effective to go 
straight to whole genome sequencing (WGS). This was 
demonstrated by the simultaneous detection of the 
mutation underlying Miller syndrome by WGS of a 
family consisting of two affected siblings and their 
parents with the added bonus of being able to calculate a 
human intergenerational mutation rate of approximately 
1.1  ×  10-8 per position per haploid genome [12]. Many 
researchers have previously reviewed the success and 
promises of whole exome or genome sequencing in 
research settings [13-19]. Here, we describe the ongoing 
developments and challenges for the clinical application 
of whole exome or genome sequencing, and we discuss 
strategies to move the field forward.
There are ongoing and rapid developments in sequen-
cing technology (Boxes 1 and 2). We consider whether a 
centralized model for whole exome or genome sequen-
cing might take advantage of economies of scale and 
increased efficiency brought about by sequencing in a 
central location. Such a model of centralized WGS could 
be a much needed ‘disruptive innovation’ [20,21], if 
implemented well. When the company Amazon first 
started, not many people would have predicted that it 
would supplant many physical bookstores, but that is 
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The pace of exome and genome sequencing is 
accelerating, with the identification of many new 
disease-causing mutations in research settings, and 
it is likely that whole exome or genome sequencing 
could have a major impact in the clinical arena in the 
relatively near future. However, the human genomics 
community is currently facing several challenges, 
including phenotyping, sample collection, sequencing 
strategies, bioinformatics analysis, biological validation 
of variant function, clinical interpretation and validity 
of variant data, and delivery of genomic information to 
various constituents. Here we review these challenges 
and summarize the bottlenecks for the clinical 
application of exome and genome sequencing, and we 
discuss ways for moving the field forward. In particular, 
we urge the need for clinical-grade sample collection, 
high-quality sequencing data acquisition, digitalized 
phenotyping, rigorous generation of variant calls, 
and comprehensive functional annotation of variants. 
Additionally, we suggest that a ‘networking of science’ 
model that encourages much more collaboration 
and online sharing of medical history, genomic 
data and biological knowledge, including among 
research participants and consumers/patients, will 
help establish causation and penetrance for disease 
causal variants and genes. As we enter this new era 
of genomic medicine, we envision that consumer-
driven and consumer-oriented efforts will take center 
stage, thus allowing insights from the human genome 
project to translate directly back into individualized 
medicine.
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indeed what has occurred. Similarly, a company that can 
implement an effective centralized sequencing facility 
and return of genomic data via the internet or using a 
secure cloud computing architecture could capture a 
portion of consumer- and hospital-oriented WGS, perhaps 
augmenting the efforts of localized and academic-based 
sequencing centers. The industrialization of WGS could 
also raise the quality standards. An example of 
industrialization relates to the current manufacturing of 
oligonucleotide primers used all over the world for 
polymerase chain reaction (PCR): nowadays most 
researchers order primers from centralized companies 
rather than synthesizing primers at local laboratories, 
mainly because these companies have achieved higher 
quality at a reduced price. Some WGS is indeed already 
being performed in central locations by at least two 
companies: Illumina (San Diego, California, USA) and 
Complete Genomics (Mountain View, California, USA). 
The key question will be whether clinicians and hospitals 
will be willing to send out DNA samples to a centralized 
location, rather than setting up the sequencing machines 
and bioinformatics resources locally. A compromise 
might be along the lines of what has occurred with the 
disruptive technology magnetic resonance imaging 
(MRI), which has been deployed in many hospitals but 
also at stand-alone MRI diagnostic centers throughout 
the USA.
Over the past 3  years, there has been a period of 
primarily exome sequencing while awaiting a further 
decrease in cost for WGS [22]. There have now been, as 
of July 2012, 747 publications involving exome studies 
(according to PubMed searching with the term ‘exome’). 
So far, the main achievements of exon capture and 
high-throughput sequencing in genomic medicine have 
been the identification of the causes of many clinically 
characterized Mendelian disorders (that is, single gene 
disorders). Furthermore, exome sequencing has been 
applied to the study of a multigenerational pedigree [23] 
and has also been used in molecular diagnostics (for 
example, to diagnose neonatal diabetes [24] and an X-
linked inhibitor of apoptosis deficiency, with the latter 
prompting an allogeneic hematopoietic progenitor cell 
transplantation with promising results [25]). In 2011, X-
chromosome exon capture and sequencing was used to 
determine the genetic basis of a previously undescribed 
and idiopathic disorder, later named Ogden syndrome, 
which was shown to result from a defect in the amino-
terminal acetylation of proteins [26]. Since that time, 
many other idiopathic disorders have been identified and 
their genetic basis determined via exome sequencing 
[27-30]. Many groups are also applying exome sequen-
cing to the study of complex diseases or traits such as 
height, hypertension, diabetes and autism, resulting in 
the identification of rare variants that might play a role in 
human diseases [31-34].
As the cost of capturing and sequencing exomes has 
decreased, it has become easier to identify the genetic 
causes of very rare Mendelian diseases. The major caveat 
here is that the causative mutation must be present in the 
currently annotated exome, and we do not have a clear 
idea of how many diseases will be caused by mutations 
outside the exome, including in non-coding regulatory 
regions [35]. Informal polling of many human geneticists 
suggests that exome sequencing projects currently 
identify a truly causative variant in only about 10% to 
50% of cases, although this estimate is very rough given 
Box 1. Progress in the application of genome sequencing
Researchers are currently sequencing thousands of exome and whole genomes, and the reagent costs for sequencing a whole genome 
may be as low as US$1,000 in the next couple of years. However, the sequencing technologies and methods used vary widely among 
researchers, and it is very much an open question how long it will take to achieve what is being called a ‘clinical-grade’ genome. We hasten 
to add that even the term ‘whole genome sequencing’ is misleading, as there are parts of the genome that are not readily amenable to 
sequencing, particularly with the current short-read sequencing technologies [131]. A newly published long fragment read technology 
may overcome many of these issues [132]. However, consistent and reproducible interpretation of the available genomic data and 
translation of the genetic findings into meaningful clinical action will be the more difficult and potentially most expensive part. A new 
generation of sequencing platforms that performs high-throughput sequencing (HTS) has now made it possible for individual laboratories 
to generate enormous amounts of DNA sequence data [133]. The inclusion of transcriptome sequencing, chromatin-immunoprecipitation 
(ChIP) sequencing and epigenetic analyses at unprecedented resolution has enabled the detection of subtle variations such as alternative 
splicing of individual exons, or base-pair-level binding preferences. There is no doubt that the ongoing avalanche of sequencing data will 
advance functional genomics studies [134,135], human disease studies [136], population genetics studies [137], metagenomics [138], 
clinical diagnosis [139], as well as other areas of biomedical importance. HTS data will also provide the foundation for new strategies in 
systems biology and individualized medicine. The miniaturization of sequencers with the advent of Illumina’s MiSeq and Life Technologies’ 
Ion Torrent is making HTS accessible to many more customers in clinical diagnostics, although incorporating these devices into clinical 
workflows will require substantive testing and validation. The development of newer technologies, including nanopore sequencing [140], 
could bring about substantially lowered cost, increased convenience, and a potentially simplified bioinformatics pipeline with longer 
sequence reads. A major drawback of these technologies pertains to possibly higher error rates.
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that most researchers do not publish their results (or lack 
thereof) when exome sequencing fails to identify a 
causative variant. This estimate is also crucially depen dent 
on one’s definition and threshold for proof of causation.
Challenges in the application of genome 
sequencing to identify causal mutations
Recently published whole exome and whole genome 
sequencing studies have taught us a great deal about the 
challenges and obstacles of finding disease causal 
mutations. In this section, we review the recent studies 
and discuss their implications for the implementation of 
genomic medicine in clinical settings. Some of these 
challenges are summarized in Table 1.
Investigating Mendelian diseases in research or clinical 
settings
Although there are successes in using genome or exome 
sequencing on single patients or small nuclear families to 
identify new causal disease mutations, these should be 
considered rare exceptions given that it is incredibly 
difficult to prove causality for any mutation (that is, that 
it is both necessary and sufficient to be the genetic cause) 
with only one affected individual. In fact, some have 
suggested that a prerequisite for new disease gene 
identification should include finding more than one 
mutation in one gene in more than one pedigree [36]. In 
the current fragmented healthcare system, one can 
imagine that it can be incredibly difficult to find a second 
pedigree for very rare idiopathic conditions. In our own 
study on Ogden syndrome, we were very fortunate during 
peer review of our manuscript to find a second pedigree 
with exactly the same missense mutation, but we have yet 
to find an additional mutation in this same gene in a third 
family [26]. Most exome sequencing studies of idiopathic 
Mendelian diseases would benefit from a substantial 
collection of cases, or at least multigenerational pedigrees 
with two or more affected cases, especially when the 
disease has a dominant inheritance pattern. It is possible 
that behind every success story in finding new genes for 
Mendelian diseases, there are several unpublished 
failures. On the other hand, if the causal gene has already 
been identified for a Mendelian disease, then it is 
relatively straightforward to perform whole exome or 
genome sequencing on patients to confirm the genetic 
diagnosis of the disease and find potential new causal 
variants in the known gene. In other words, larger sample 
sizes are required in research settings for finding causal 
mutations in new genes, whereas genetic interpretation is 
feasible for individual patients with known Mendelian 
diseases in clinical settings with access to databases of 
known disease-causing variants [37].
Adequate sample selection for any exome or genome 
sequencing study is important, given that the bioinformatics 
Box 2. ethical issues and practical issues with clinical genome sequencing
In 2011, we discussed how we pursued and handled an unrelated finding emerging from exome sequencing [38], and one of us discussed 
the ethical, clinical and practical implications of exome and genome sequencing [141,142]. The argument has also been presented that 
‘there is nothing incidental about unrelated findings’, and we consider the term ‘incidental’ to be misleading because use of this term 
trivializes, at least in the mind of the public, the amount of work that ought to go into figuring out causality for unrelated, unanticipated 
or secondary results (all of which are more suitable terms for such a finding) [143]. We are fast approaching a period in which thousands of 
human genomes will be sequenced, and we advocate for at least the initial germline genome of each person to be sequenced in a clinical 
grade manner, which includes adequate sample collection, tracking and sequencing in Clinical Laboratory Improvements Amendment 
(CLIA)-certified laboratories in the USA, so that researchers can return these results to research participants. Already, the company Illumina 
(San Diego, California, USA) has a CLIA-certified whole genome sequencing (WGS) pipeline (Box 1), and several companies, including 
23andMe (Mountain View, California, USA) and Ambry Genetics (Aliso Viejo, California, USA), offer CLIA-certified whole exomes. Several 
academic institutions are also rapidly moving toward the implementation of CLIA-certified exome and whole genome pipelines in their 
facilities. We fully expect that the barrier to the clinical-grade sequencing of germline genomes, preferably from blood-derived DNA, will 
be substantially lower in 12 months’ time, thus allowing a huge increase in such sequencing to occur. Several academic medical centers 
are initiating WGS projects, and we expect that this trend will increase as hospital leaders, executives and insurance companies realize 
that a germline genome is far cheaper than the current practice of single gene diagnostic odysseys, which can sometimes cost up to 
US$100,000 and stretch over several years [144].
The current CLIA-certified WGS at Illumina is performed with an average sequencing depth of more than 30×, with more than 95% of all 
calls made at a depth of greater than 10 reads or more. One could also increase coverage and accuracy by sequencing the same sample 
on two separate platforms (for example, Illumina and Complete Genomics) and using only shared variants as determined by one variant 
calling platform (for example, Genome Analysis Toolkit, GATK) [145]. However, this may currently be impractical due to storage and 
economic considerations, although we expect that this approach could become much more plausible in the future. As an alternative, for 
now, one could minimize cost but increase accuracy by only using variants called by two or more variant-calling approaches on one set 
of sequencing data. Additionally, there are different expectations and tolerances to false positives in a research setting versus in a clinical 
setting, and there is therefore a need to apply different filtering strategies in different settings. There will be constant improvements with 
assembly and variant-calling algorithms, so that the overall accuracy of WGS will always be improving [146].
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Table 1. Considerations and challenges for the identification of disease causal mutations
Considerations Challenges Solutions
Mutation detection Platform selection Different sequencing platforms have 
variable error rates
Increased sequencing coverage for platforms with high 
error rates
Sequencing target selection Exome sequencing may miss regulatory 
variants that are disease causal
Use whole genome sequencing when budget is not 
a concern, or when diseases other than well-studied 
classical Mendelian diseases are encountered
Variant generation Genotype calling algorithms differ from 
each other and have specific limitations
Use multiple alignment and variant calling algorithms 
and look for concordant calls. Use local assembly to 
improve indel calls
Variant annotation Multiple gene models and multiple 
function prediction algorithms are 
available
Perform comprehensive set of annotations and make 
informed decisions; use probabilistic model for ranking 
genes/variants
Variant validation Predicted disease causal mutations may 
be false positives
Secondary validation by Sanger sequencing or capture-
based sequencing on specific genes/regions
Type of mutations Coding and splice variants Many prediction algorithms are 
available
Evaluate all prediction algorithms under different 
settings. Develop consensus approaches for combining 
evidence from multiple algorithms
Untranslated region, synonymous 
and non-coding variants
Little information on known causal 
variants in databases such as HGMD
Improved bioinformatics predictions using multiple 
sources of information (ENCODE data, multispecies 
conservation, RNA structure, and so on)
Specific application 
areas
Somatic mutations in cancer Tissues selected for sequencing may 
not harbor large fractions of cells with 
causal mutations due to heterogeneity; 
variant calling is complicated by 
stromal contamination; current 
databases on allele frequencies do not 
apply to somatic mutations; current 
function prediction algorithms focus on 
loss-of-function mutations
Sample several tissue locations for sequencing; 
utilize algorithms specifically designed for tumor 
with consideration for heterogeneity; use somatic 
mutation databases such as COSMIC; develop function 
prediction algorithms specifically for gain-of-function 
mutations in cancer-related genes/pathways
Non-invasive fetal sequencing Variants from fetal and maternal 
genomes need to be teased apart; 
severe consequences when variants are 
incorrectly detected and predicted to 
be highly pathogenic
Much increased sequence depth and more 
sophisticated statistical approaches that best leverage 
prior information for inferring fetal alleles; far more 
stringent criteria to predict pathogenic variants
Inheritance pattern Inherited from affected parents Rare/private mutations may be neutral Evaluate extended pedigrees and ‘clans’ to assess the 
potential role of private variants
De novo mutations from 
unaffected parents
Every individual is expected to carry 
three de novo mutations, including 
about one amino acid altering 
mutation per newborn
Detailed functional analysis of the impacted genes
Biological validation Known disease causal genes Difficult to conclude causality when 
a mutation is found in a well-known 
disease causal gene
Examine public databases such as locus-specific 
databases
Previously characterized genes 
not known to cause the disease 
of interest
Relate known molecular function to 
phenotype of interest
Evaluate loss of function by biochemical assays where 
available
Genes without known function Difficult to design functional follow-up 
assays
Evaluate gene expression data. Use model organisms 
to recapitulate the phenotype of interest
Statistical validation Rare diseases Limited power to declare association Sequence candidate genes in unrelated patients to 
identify additional causal variants
Idiopathic diseases Lack of additional unrelated patients Comprehensive functional follow-up of the 
biospecimens from patients to prove causality
Mendelian diseases or traits Finding rare, unrelated individuals with 
same phenotype and same mutation 
to help prove causality
Networking of science through online databases 
can help find similarly affected people with same 
phenotype and mutation
Type of phenotypes Mendelian forms of complex 
diseases or traits
Several major-effect mutations may 
work together to cause disease
Statistical models of combined effects (additive and 
epistatic) of multiple variants within each individual
Complex diseases or traits Many variants may contribute to 
disease risk, each with small effect sizes
Refrain from making predictions unless prior evidence 
suggested that such predictive models are of practical 
utility (for example, receiver operating characteristic 
>0.8)
HGMD, Human Gene Mutation Database.
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analysis is aided tremendously by the appropriate selec-
tion of accurately phenotyped ‘normal’ or ‘unaffected’ 
individuals in a pedigree. For us, the exome sequencing 
of a quartet with dominantly inherited symptoms of 
attention-deficit hyperactivity disorder was insufficient 
to prove causality for any of the rare variants that we 
identified [38]. In contrast, for Ogden syndrome, sequen-
cing a proband with a new idiopathic disease, presumed 
carrier mother, presumed carrier grandmother, unaffected 
brother and unaffected uncle in a pedigree allowed the 
identification of a potentially causative mutation, followed 
by confirmation with segregation analysis in affected and 
unaffected members of the family [26], illustrating the 
importance of good pedigree collections. Having access 
to clearly unaffected members of the family also allows 
one to eliminate sources of systematic error in the 
sequencing data by eliminating from consideration those 
variants also found in unaffected members [39].
Appropriate tissue selection
Whole genome or exome sequencing studies typically use 
DNA samples derived from peripheral blood. However, 
several recent studies demonstrated the presence of 
hematopoietic mosaicism [40,41]. The extent of such 
hematopoietic mosaicism among the population is not 
well studied, and its influence on variant calls remains 
largely unknown. When blood samples are not available, 
other tissues may be used, with buccal samples being the 
most common due to the non-invasive sampling and the 
commercial availability of kits for high-quality DNA 
extraction. It should be noted that buccal samples may be 
heavily contaminated by bacterial and food content, and 
these facts should be considered in bioinformatics analy-
sis and data interpretation. Additionally, other sources of 
DNA can also be assayed under specific settings, such as 
skin or hair samples in forensic settings, or bones or teeth 
in archeological settings, all with their own caveats for 
choosing sequencing and analysis strategies.
For studies on somatic mutations in cancer, a tumor 
sample is typically used together with a germline sample 
(adjacent normal tissue or peripheral blood). It should be 
noted that adjacent normal tissue may still contain 
initiating mutations that are important for subsequent 
cancer progression. In some cases, tumor samples are 
stored in formalin-fixed paraffin-embedded conditions. 
They can be still used in whole-genome or exome 
sequencing with help from commercial kits, but one 
should expect lower data quality, and should carefully 
select the sequencing platform and library construction 
methods, given the fragmented nature of these archival 
DNA samples. Additionally, some non-cancerous diseases 
of specific tissues may involve somatic mutations, as 
somatic copy number variations (CNVs) can be identified 
in differentiated tissues within the same human subjects 
[42]. If neurological diseases such as epilepsy and 
schizophrenia are related to somatic mutations at specific 
brain regions, the evaluation of tissues at lesion sites may 
offer biological insights that are unattainable from 
peripheral blood. We discuss more about somatic 
mosaicism below.
Determining the precise phenotypic characteristics of 
diseases
Over 5,000 confirmed or suspected Mendelian pheno-
types have already been documented in the Online 
Mendelian Inheritance in Man (OMIM) database, and 
each of them is represented by a set of specific phenotypic 
features or diagnostic criteria (although admittedly there 
are many non-specific diseases documented there). There 
is also a catalog of human genetic mutations in the 
Human Genome Mutation Database. In clinical settings, 
however, the exact disease diagnosis is sometimes 
difficult to make due to variable expressivity of disease 
variants, the phenotypic similarity of some diseases and 
the presence of modifier genes, even for classical 
Mendelian diseases. It is likely that a precise charac ter i-
za tion of each patient is best accomplished by correlating 
genomic information and longitudinal phenotypic 
information with each other, thus enabling more accurate 
diagnoses. In light of this, we envision that a digitalized, 
longitudinal and more comprehensive description of 
pheno types will be especially important for accurate identi-
fication of disease genes in clinical genomic sequencing.
Many community efforts are being undertaken to 
accurately assess phenotypes, including the use of 
standardized vocabularies and/or specialized diagnostic 
tests to refine the precise phenotypic characteristics of 
diseases. In the world of electronic medical records, there 
are many ongoing projects to develop more precise 
ontologies, including a Unified Medical Language System 
and a Systematized Nomenclature of Medicine Clinical 
Terms [43]. The International Statistical Classification of 
Diseases and Related Health Problems 10th Revision 
(ICD-10) is a medical classification list developed by the 
World Health Organization for the coding of diseases, 
signs and symptoms, abnormal findings, complaints, 
social circumstances, and external causes of injury or 
diseases [44]. This classification allows more than 14,400 
different codes for specific phenotypes and permits the 
digitalized description of phenotypic features or sus-
pected disease traits. The Human Phenotype Ontology 
(HPO) project has also been proposed to address this 
challenge [45]. The project provides a standardized 
vocabu lary of phenotypic abnormalities encountered in 
human disease. It has over 8,000 terms representing 
individual phenotypic anomalies and has annotated all 
clinical entries in OMIM with the terms of the HPO. 
Within specific disease areas, clinicians are also 
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developing specialized tests that better define phenotypic 
characteristics, especially for hard-to-diagnose diseases 
such as psychiatric disorders that do not depend on 
biochemical measurements or biopsies. For example, the 
Research Domain Criteria have been proposed as new 
ways of classifying psychopathology based on dimensions 
of observable behavior and neurobiological measures, 
thus reducing reliance on the semantics of traditionally 
defined disorders (such as autism, schizophrenia and 
bipolar disorder).
Collectively, adoption of these standardized and 
digitalized diagnostic criteria will help shape the 
phenotypic characterization of individual patients, 
identify specific sets of candidate diseases that may fit the 
phenotypic descriptions, and help to better identify and 
prioritize candidate genes for diseases in clinical settings. 
On the other hand, more refined phenotypic assessments 
come with the price of fewer available samples and less 
power to detect disease variants and genes. In practice, 
investigators often have to work with different factors, 
including being more inclusive in study design or 
conduct, and applying varying thresholds on phenotype 
during data analysis, to increase the odds of identifying 
disease causal genes and variants. For example, in the 
Kabuki syndrome study [11], the authors assessed the 
severity of each patient and identified the causal mutation 
only in the set of patients with more severe phenotypes.
The presence of loss of function mutations
Loss of function (LoF) variants can be classified as those 
that completely ablate or decrease protein function, and 
include nonsense mutations, splice site-disrupting muta-
tions, insertions or deletions that disrupt a transcript’s 
reading frame, or deletions encompassing a large part of 
protein-coding sequence. A recent study showed that 
genomes from healthy human subjects contain many LoF 
variants, suggesting unexpected redundancy in the 
human genome [46]. This well-designed study showed 
that each genome typically contains approximately 100 
genuine LoF variants with about 20 genes completely 
inactivated and the others partially inactivated [46]. 
There fore, the presence of a gene with two LoF variants 
in a personal genome does not automatically mean that 
the person will have a disease phenotype.
The establishment of databases of LoF variants, together 
with careful evaluations of the known functional 
evidence in the context of the phenotypes of interest, will 
be required to determine if a gene with LoF mutations is 
truly causal, at least within particular genetic backgrounds.
The complexity of disease and modes of inheritance
There are approximately 6 billion nucleotides of DNA in 
every cell of the human body, and there are about 50 to 
75 trillion cells in each human body. This genetic 
complexity is further complicated by somatic mosaicism, 
epigenetic changes and other possible phenomena (such 
as heterosis, otherwise known as hybrid vigor, deter-
mined by non-mutually exclusive mechanisms like domi-
nance complementation, overdominance and epistasis 
[47]). Many severe Mendelian diseases are caused by LoF 
variants. For example, in Kabuki syndrome, a dominantly 
inherited multiple malformation disorder characterized 
by a distinctive facial appearance, cardiac anomalies, 
skeletal abnormalities, and mild to moderate intellectual 
disability, among 32 disease mutations found in 53 
families, 27 (20 nonsense mutations and 7 indels) resulted 
in a premature stop codon [11,48]. However, it is worth 
noting that many Mendelian diseases are also caused by 
missense mutations, with an example being Ogden 
syndrome, caused by a single amino acid change from a 
serine to a proline.
Although many Mendelian diseases can be classified as 
dominant, recessive, inherited or de novo, some Mende-
lian diseases or the Mendelian categories of complex 
diseases typically do not fall within clear-cut definitions. 
Instead, Mendelian forms of complex diseases can have 
genetic heterogeneity, including allelic heterogeneity and 
also heterogeneity in the mode of inheritance. For 
example, exome sequencing of 41 families with hyper-
tension and electrolyte abnormalities identified two 
causal genes, encoding kelch-like 3 (KLHL3) and cullin 3 
(CUL3) proteins [33]. However, KLHL3 mutations were 
either recessive or dominant, whereas CUL3 mutations 
were dominant and predominantly de novo. Therefore, 
caution should be taken when interpreting personal 
genomes with Mendelian forms of complex diseases, as 
the mode of inheritance may not be known a priori, and 
there are the combined complexities of locus hetero-
geneity, mixed models of transmission and de novo muta-
tion. In addition, the presence of modifier genes can also 
have dramatic effects [49]. Somatic mosaicism is an 
increasingly recognized phenomenon in some diseases 
[50-53]. Proteus syndrome, which is characterized by the 
overgrowth of skin, connective tissue, brain and other 
tissues, was shown to be caused by a somatic activating 
mutation in the oncogene AKT1, encoding an enzyme 
involved in processes such as cell proliferation and 
apoptosis, proving that somatic mosaicism and activation 
of the PI3K-AKT (phosphoinositide 3-kinase - serine-
threonine protein kinase) pathway underlies overgrowth 
and tumor susceptibility in this disorder [53]. Another 
group showed that ichthyosis with confetti, a severe, 
sporadic skin disease in humans, is associated with 
thousands of revertant clones of normal skin that arose 
from spontaneous loss via mitotic recombination of a 
region on chromosome 17q containing disease-causing 
mutations in the gene encoding keratin 10 (KRT10). They 
further suggested that either the revertant stem cell 
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clones are under strong positive selection and/or that the 
rate of mitotic recombination is elevated in individuals 
with this disorder [54]. To complicate matters further, 
another group showed that retrotransposition of long 
interspersed nuclear elements-1 (LINE-1 or L1s), which 
are abundant retrotransposons that comprise approxi-
mately 20% of mammalian genomes, during brain develop-
ment can have an impact on gene expression and neuronal 
function, thereby increasing brain-specific genetic 
mosaicism. They further showed that L1 retro trans-
position can be controlled in a tissue-specific manner 
and that disease-related genetic mutations can influence 
the frequency of neuronal L1 retrotransposition [55].
In summary, the complexity of diseases and their mode 
of inheritance may help us prioritize variants (such as 
focusing on nonsense variants that arise de novo for a 
specific disease). On the other hand, investigators should 
be aware of the possibility of heterogeneous patterns of 
disease between families when performing data analysis.
The need for biological validation of causality for 
previously uncharacterized variants
Many novel variants will be discovered from exome and 
genome sequencing. In some cases, the causality is self-
evident if the variant leads to severe loss of function and 
is located in a gene known to cause the phenotype of 
interest. In many other cases, especially for uncharac ter-
ized diseases and/or isolated cases, biological validation 
is necessary to prove the causality of the disease variants. 
Unfortunately, biological validation takes a substantial 
amount of time and effort, which can easily exceed the 
time taken for the original sequencing experiments. For 
example, a de novo mutation in the gene encoding 
sodium channel SCN8 was suspected to cause infantile 
epileptic encephalopathy in a single family, and the 
researchers analyzed biophysical properties of the mutant 
by current-clamp analysis in hippocampal neurons 
transfected with the mutant gene [56]. We identified a 
mutation in an amino-terminal acetyltransferase gene 
NAA10 as a potential disease causal gene for Ogden 
syndrome, but the establishment of causality came after 
in vitro studies of the mutated protein, showing com-
promised amino-terminal acetylation. It was only much 
later that further confirmation came from a second 
unrelated family with the same phenotype and mutation 
[26]. Similarly, mutations in the heat shock protein co-
chaperone BCL2-associated athanogene 3 (BAG3) were 
suspected to be causal for dilated cardiomyopathy in one 
family, yet to truly establish the functional relevance, the 
researchers performed knockdown of BAG3 in a 
zebrafish model and recapitulated dilated cardiomyo-
pathy and heart failure [57]. Biological validation in cell 
culture or various model organisms such as zebrafish and 
mice can therefore be extremely important to establish 
causality for uncharacterized variants and genes, 
particularly when mutations are only identified in one 
family.
Some previously identified disease causal variants may be 
false positives
Next-generation sequencing on large human populations 
could now enable the establishment of databases 
documenting allele frequencies of genetic variants, and 
such databases can provide a platform to separate very 
rare variants (potentially causal for Mendelian diseases) 
from low-frequency polymorphisms. Many previously 
reported ‘private’ causal variants have now been found to 
be present with low allele frequencies in apparently 
healthy human populations and are thus unlikely to be 
truly causal or at least are modified by genetic back-
ground effects. For example, among 197 previously 
published rare variants reported as causative of dilated 
cardiomyopathy, 33 were also present in the National 
Heart, Lung, and Blood Institute-Exome Sequencing 
Project (NHLBI-ESP) database (composed of many 
subjects from a well-phenotyped population), raising the 
possibility that some of the variants identified as disease-
causing in sporadic dilated cardiomyopathy are either 
false positives or low penetrance alleles in human 
populations [58]. This example underscores the impor-
tance of public databases on allele frequencies from large 
collections of samples, such as the 1000 Genomes Project 
and the NHLBI-ESP projects, in helping researchers and 
clinicians decide on the clinical relevance of specific 
variants in personal genomes.
A leading example in human genetics concerning 
genetic background effects involves the concept of tri-
allelism, which has been advocated to explain variable 
penetrance in Bardet-Biedl syndrome, a phenotype 
defined by the association of retinitis pigmentosa, 
obesity, polydactyly, hypogenitalism, renal disease and 
cognitive impairment [59-61]. This model of tri-allelism 
invokes a third allele in a separate gene as being 
sometimes involved in the variable expressivity of the 
phenotype, but this has been challenged by others 
[62-66], and at least one group maintains that all 
individuals that they have studied with two autosomal 
recessive mutations in the same gene have 100% 
penetrance, but with variable expressivity (that is, one 
individual might have retinitis pigmentosa only, whereas 
another individual might have the full-blown symptoms 
of Bardet-Biedl syndrome [62]). We consider that careful, 
longitudinal phenotyping of individuals with Mendelian 
diseases will be necessary for determining the true effects 
of modifier loci. This is one major reason why we support 
a ‘networking of science’ approach (see below), including 
consumer and patient engagement with various online 
phenotyping tools (for example, PatientsLikeMe).
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Bioinformatics challenges in interpreting personal 
genomes in clinical settings
There is a growing gap between the generation of 
massively parallel sequencing output and the ability to 
process, analyze and interpret the resulting data. New 
users of sequencing technologies are left to navigate a 
bewildering maze of base calling, alignment, assembly 
and analysis tools. Many software tools developed for 
sequencing data are not sufficiently robust and can only 
work on one type of data generated from one type of 
sequencing experiment, limiting the ability to obtain 
critical biological insights. Additionally, many of the 
academic software tools are not well maintained or 
documented, perhaps due to the lack of support, funding 
or motivation after publication of the methodology or 
software tools. Bridging these gaps is essential, or the 
coveted US$1,000 genome will come with a US$20,000 or 
US$100,000 analysis price tag [67,68]. In fact, the 
challenging nature of bioinformatics prevents many 
biologists from embracing the new sequencing tech-
nologies because of the difficulties involved in analyzing 
the vast quantities of resulting data, which we refer to as 
the ‘Genomic Deluge’.
There has been growing awareness in the genomics 
community of the need for novel informatics solutions, 
including better methods for aligning sequencing reads, 
variant identification, genotype calling and association 
tests, in order to take advantage of the massive amounts 
of sequencing data. In fact, dozens of short read 
alignment software programs are available now with 
different functionalities [69], as well as several single 
nucleotide variant and CNV calling algorithms [70]. 
However, in addition to identifying variants accurately, 
interpreting the functional impacts for large amounts of 
sequencing data is important to pinpoint potential 
disease causal genes and mutations.
Over the past 2  years, several variant annotation 
pipelines have been developed by many different groups 
[26,71-78]. In Table 2, we have summarized some current 
software tools that are capable of annotating genetic 
variants from high-throughput sequencing data. Many of 
these software tools include the ability to report in silico 
protein prediction scores, but they also include many 
more functionalities. We recognize that the community 
as a whole has performed extensive research on develop-
ing bioinformatic solutions for predicting the functional 
importance of certain classes of variants such as non-
synonymous SNPs. Despite the availability of many such 
algorithms, different algorithms use different information 
and each has its own strengths and weaknesses (Table 1). 
Several groups have worked on improving the various 
scoring systems for judging the possible extent of the 
deleterious effects of a mutation [79-92]. However, 
predictions from different algorithms typically do not 
agree well: for example, only 5% of deleterious predictions 
were found to be shared between well-known algorithms 
(SIFT [82], Polyphen2 [93], LRT [94]) on a data set of 
three human genomes [94]. One group used data from 
the pilot3 study of the 1000 Genomes Project, available 
through Genetic Analysis Workshop 17, to compare (in 
blinded fashion) the results of four programs (SIFT, 
PolyPhen, MAPP and VarioWatch) used to predict the 
functional relevance of variants in 101 genes. The results 
modestly overlapped in the range of 59.4% to 71.4%, with 
only 3.5% of variants classified as deleterious and 10.9% 
as not damaging across all four programs [83]. It has been 
suggested that investigators should use predictions from 
multiple algorithms instead of relying on a single one 
[94]. As a preliminary step to facilitate the process, 
dbNSFP (database for non-synonymous SNPs’ functional 
predictions) was developed. It compiles prediction scores 
from four popular algorithms (SIFT, Polyphen2, LRT and 
MutationTaster [92]), along with a conservation score 
(PhyloP) and other related information, for every 
potential non-synonymous variant in the human genome. 
However, these annotations are far from comprehensive, 
and we expect that more accurate predictions may be 
generated using additional information. Furthermore, 
other classes of variants, including synonymous, UTR, 
splicing and intergenic variants, are much less well 
studied, yet recent studies highlight their potential func-
tional significance in human disease [95-98]. Therefore, 
the lack of comprehensive and powerful approaches for 
functional prediction is impeding the progress to study 
newly discovered variants, especially non-coding variants, 
for their involvement in human disease.
With functional annotation of variants in hand, there 
are two general strategies for inferring candidate genes: a 
probabilistic scoring approach and a stepwise filtering 
approach (Figure 1). The former approach is conceptually 
more sophisticated and less likely to miss truly causal 
variants, but the latter approach is currently more easily 
interpretable by researchers and clinicians without bio-
informatics skills, and is therefore more widely used. 
Various bioinformatics tools, including those in Table 2, 
offer the ability to filter variants based on user-specified 
criteria and help with the identification of disease genes.
Disease-specific assignment of functional importance
Although all current software tools predict whether a 
variant is likely to be deleterious (for example, adversely 
affects protein or genome functionality), a more 
important question is whether the variant causes or 
modifies a certain disease of interest. For example, many 
genes encoding olfactory receptors are deleted in any 
human genome, but they can be safely ignored when 
analyzing Mendelian diseases. Therefore, we urge that 
disease- or application-specific treatment of genetic 
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variants is needed, beyond simple variant annotation. 
There are several important reasons to pursue this 
approach. Firstly, conventional protein functional predic-
tion algorithms only provide a binary prediction on 
whether a variant is deleterious or tolerated. However, a 
defect in protein function does not necessarily mean that 
a specific phenotype will be affected and investigators 
often have to search for clues on the specific disease 
classes (for example, cancer, immunological or cardio-
vascular traits) that the variant may influence. With this 
information in hand, biologists can design experiments 
to test the functionality of the variants in the context of 
Table 2. A list of open-access bioinformatics software tools or web servers that can perform batch annotation of genetic 
variants from whole-exome/genome sequencing data*




A software tool written in 
Perl to perform gene-based, 
region-based and filter-based 
annotation
Rapid and up-to-date annotations 
for multiple species; thousands of 
annotation types are supported
Requires format conversion 
for VCF files; command line 




A software tool written in 
Python to annotate SNVs, indels 
and CNVs
Fast information retrieval by 
MySQL database engine; output in 
VCF format for easy downstream 
processing
Only supports human genome 
build 37; does not annotate 




A Java web application for 
variant annotation
Web interface for users with limited 
bioinformatics expertise; output in 
Excel and text formats




A web server that provides 
annotation on known and 
novel SNPs
Multiple input formats are supported; 
users can customize annotation tasks




[http://www.svaproject.org/] A graphical Java software tool 
to annotate, visualize and 
organize variants
Intuitive graphical user interface; 
ability to prioritize candidate genes 
from multiple patients
Functionality is not very 
customizable; depends 




A command-line software 
tool to calculate the effects of 
variants on known genes such 
as amino acid changes
Rapid annotation on multiple 
species and genome builds; supports 
multiple codon table





A command-line software 
tool with rich integration of 
publicly available and in-house 
developed annotations
An Amazon Cloud Image is available 
for users with limited bioinformatics 
infrastructure; offers a complete set 
of pipelines to process FASTQ files 
and generates annotation outputs
Only supports ENSEMBL gene 




A command-line software tool 
implementing a probabilistic 
disease-gene finder to rank all 
genes
Prioritize candidate genes for 
Mendelian and complex diseases
Main focus is disease gene 
finding with limited set of 
annotations
VARIANT [http://variant.bioinfo.cipf.es] A Java web application 
for variant annotation and 
visualization
Intuitive interface with integrated 
genome viewer
Highly specific requirement 




A graphical Java program 
to display, sort, filter and sift 
variation data
Nice graphical user interface; 
allows interaction with Integrative 
Genomics Viewer
Main focus is variant filtering 
and visualization with limited 
functionality in variant 
annotation
VAT [http://vat.gersteinlab.org/] A web application to annotate 
a list of variants with respect 
to genes or user-specified 
intervals
Application can also be deployed 
locally; can generate image for genes 
to visualize variant effects
Requires multiple other 
packages to work; only 
supports gene-based 
annotation by GENCODE
wANNOVAR [http://wannovar.usc.edu/] A web server to annotate user-
supplied list of whole genome 
or whole exome variants with 
a set of pre-defined annotation 
tasks
Easy-to-use interface for users with 
limited bioinformatics skills
Limited set of annotation types 
are available
*Tools that are only commercially available (such as CLC Bio, Omicia, Golden Helix, DNANexus and Ingenuity) or are designed for a specific type of variant (such as SIFT 
server and PolyPhen server) are not listed here. CNV, copy number variation; SNP, single nucleotide polymorphism; SNV, single nucleotide variation; VCF, variant call 
format.
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in vivo or in vitro models for the specific diseases of 
interest. Secondly, it is common practice to use prior 
knowledge of particular rare variants when trying to 
understand their clinical significance. For example, since 
the cholesteryl ester transfer protein gene, CETP, is 
associated with cardiovascular diseases [99], then any 
rare variants within CETP could more likely contribute to 
cardiovascular diseases, compared with other diseases. 
However, this is not necessarily the case. Indeed, genes 
can pleiotropically influence risk for multiple diseases. In 
fact, a single gene may influence risk for multiple diseases 
(for example, apolipoprotein E and heart and Alzheimer’s 
diseases). Thirdly, for intergenic non-coding variants, 
large-scale projects such as ENCODE [100] provide 
ample amounts of tissue-specific information for 
assigning functional relevance. Although some enhancers 
and promoters are ‘housekeeping’ genomic elements that 
are active in most cell types, many enhancers, promoters, or 
repressors function in a tissue-specific or disease-specific 
manner, and the functional relevance of intergenic 
variants has to be assigned accordingly. For example, 
active enhancers in prostate cell lines are potentially 
more likely to contribute to prostate cancer formation 
and progression than enhancers in other cell lines; 
indeed, the 8q24 genome-wide association study (GWAS) 
hit sits inside an enhancer, and this same GWAS target 
has already been associated with several different cancers 
[101-104]. Such a region has strong existing evidence for 
involvement in cancer and is potentially less relevant for 
other types of diseases, and this information could be 
incorporated into predicting variant function.
Approaches for accelerating data collection and 
analysis
We have discussed various practical challenges and 
considerations for identifying disease-relevant mutations 
in genomic medicine settings, and we have highlighted 
some key differences compared to research settings. We 
Figure 1. Two approaches for prioritizing disease causal genes from whole-genome or exome sequencing data. (a) The probabilistic 
scoring approach collects relevant information from multiple data sources, and compiles a statistical model that ranks all genes in the genome 
by their likelihood of being disease causal. (b) The stepwise reduction approach removes variants that are unlikely to be disease causal based on 
a series of filtering criteria, until a small set of candidate genes is found. The first approach may be more effective and rigorous, yet the second 
approach may be easier for non-specialists to understand and interpret. GWAS, genome-wide association study; HGMD, Human Gene Mutation 
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have discussed ongoing community efforts to address 
these challenges, including clinical-grade sample collec-
tion, digitalized phenotyping, acquisition of high-quality 
sequencing data, rigorous generation of variant calls, 
comprehensive functional annotation of variants, and 
biological validation of variant function. In this section, 
we propose that additional crucial steps are needed to 
move the field forward and accelerate the clinical 
adoption of whole exome or genome sequencing. In 
particu lar, we strongly support the collaborative ‘net-
work ing of science’ model, which involves community 
efforts to identify disease mutations. We also discuss how 
putting more focus on families affected by specific 
diseases and ‘clan genomics’ (analysis of individuals 
sharing very recent ancestry) can help to improve the 
success of genomic medicine.
The ‘networking of science’ model
The advent of the internet and the digital age, including 
the explosion of social media, is enabling an incredible 
increase in the amount of networking worldwide. The 
increased ability to collaborate on a massive scale has 
resulted in projects such as the HapMap project [105-
107], the 1000 Genomes Project [108] and the ENCODE 
project [109], just to name a few. As presented recently 
[110], this ‘networking of science’ is also giving rise to 
much more citizen science and online patient advocacy 
groups, conducting their own research with the online 
sharing of their own data, with an example being 
PatientsLikeMe [111,112]. We consider that a ‘network-
ing of science’ model that encourages much more 
collaboration and online sharing of genomic data [113], 
including among the research participants and patients, 
will help to truly unleash the power of genome sequen-
cing in clinical applications. This model should comprise 
open-access databases on the internet, including, at the 
very least, anonymized phenotype and genomic informa-
tion. The Human Variome Project and others are working 
on standards for genome and variant annotation [114,115], 
and it will remain important to foster international 
collaborations between academic and commercial centers.
Networks form the basis of the scientific community, 
contributing to career development and the dissemi-
nation of scientific knowledge among peer groups. 
However, networks do not have to rely on persons whom 
a scientist already knows, and networks may indeed 
accelerate collaborative research with anonymous peers, 
citizen scientists, research participants and patients. In 
the genomic medicine setting, where each individual’s 
expertise and knowledge may only focus on one part of 
the genome (such as for specific genes or diseases), 
network-based collaborative investigation may become 
especially important. One major obstacle to the 
implementation of ‘networked genomic medicine’ will be 
privacy concerns, as there are many cultural, political and 
legal obstacles to the sharing of genetic data, only some 
of which have been partially alleviated in the USA with 
the Genetic Information Nondiscrimination Act of 2008. 
There are also major problems with the entire electronic 
medical record system in the USA, most recently 
articulated in a succinct commentary [116]. It is perhaps 
naive to expect that these obstacles can be overcome 
within the next 20 years, and it may very well be the case 
that there might be a 50-year time horizon on the secure 
implementation of clinical genomics and individualized 
medicine. We certainly hope that every newborn will 
have the vast majority of their genome sequenced and 
digitally available by the year 2062.
Online sharing of genomic data, phenotype data and 
biological knowledge
Traditionally, online sharing of genomic data has been 
restricted to healthy human subjects (such as the 1000 
Genomes Project) due to potential regulatory concerns. 
Recently, online sharing of patients’ data, including 
medical history, diagnosis and genome sequence infor-
mation, has been increasingly recognized as important 
for advancing collaborative scientific efforts [111,112]. 
For example, Complete Genomics has now shared genome 
sequence information for four anonymous patients with 
breast cancer online [117]. The San Antonio 1000 Cancer 
Genome Project is planning to share medical history as 
well as complete DNA sequencing for 1,000 cancer 
patients online [118]. Additionally, many individuals are 
brave enough to post their own genome data in blogs or 
personal websites, letting the whole world gain un-
restricted access [119,120]. These types of online genomic 
data sharing for disease populations or healthy subjects 
will undoubtedly arouse interest from experts in different 
scientific areas, and allow them to apply their expertise to 
find better ways to examine genomic information.
In addition to sharing of genotype or phenotype data, 
we expect that collaborative online annotation of disease 
genes and disease variants may supplement current 
bioinformatics solutions. The possibility to build a gene-
function wiki was proposed in 2006 [121] and several 
such wiki implementations were established several years 
later [122,123]. Given that different researchers or 
clinicians have different areas of expertise, it is possible 
that collaborative annotation of disease-relevant variants 
can accelerate the pace of variant prioritization with 
respect to specific disease phenotypes (much like the 
‘literature review’ procedure in Figure 1 performed by the 
community). Frameworks of collaborative variant anno-
ta tion already exist, including OMIM and GeneTalk 
[124], though OMIM is currently limited only to a small 
group of experts. It is foreseeable that the collective 
brainpower from the worldwide community of scientists 
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and citizens, through online annotation of disease 
variants, may significantly facilitate the annotation of 
disease causal mutations in clinical settings.
One can imagine that in the not too distant future, each 
person’s omics information (for example, genome, 
methy lome, transcriptome and proteome), or at least 
whole genome DNA variants, will be sequenced at birth 
and automatically deposited onto a secure website, 
perhaps in a centralized location with massive online 
storage space. In such a setting, each individual will be 
able to review pertinent genetic findings at any time, 
including any rare variants shown to increase the risk of 
any diseases by at least ten-fold or greater within the 
‘clan’ or population substructure of that particular 
individual [125,126]. Such participant-centric initiatives 
might also help to empower individuals with their own 
genomic data [127]. This will be further enabled by 
adequate ancestry and family history tracking, and one 
can already see that this is possible with social net-
working (for example, Twitter, Facebook or similar 
incarnations) and the current efforts of companies like 
23andMe and Ancestry.com.
Lastly, there is an increasing movement for genomic 
data and samples to belong to the person from which 
they are derived, and this concept of ‘portable legal 
consent’ is being championed by Sage Bionetworks [113]. 
We acknowledge the possible security concerns that 
people have to face, if they choose to release genomic 
data online, just as people currently have to maintain the 
security of their social security numbers and other 
identifiable information. We consider that it might be 
impossible to maintain complete de-identification of 
genomic DNA in the face of potential ‘genomic hackers’, 
but the benefits far outweigh potential risks, at least for 
families with devastating diseases. Increased security is 
one possible reason to support (or even require) a more 
centralized and industrialized whole germline genome 
clinical sequencing effort, although we fully realize that 
this will likely not occur in the absence of regulation at 
the federal level.
The focus on diseases in families and ‘clans’
In research settings, a research participant’s question-
naire is assessed and then samples of blood or saliva are 
obtained, with the samples kept in a de-identified manner 
among those of many other study participants. In 
comparison, in genomic medicine settings, we emphasize 
that it is extremely important to put more focus and 
effort on families with diseases. Ultimately, the families, 
rather than researchers or research funders, are those 
who will benefit most from clinical genomic sequencing 
efforts, and they have a strong desire to find disease-
relevant mutations and advance scientific discovery 
regarding these mutations. A second reason to focus on 
families is that the ability to build up personal relation-
ships with families will help to obtain further support 
from these families for research efforts. This becomes 
especially important in light of the need to perform 
biological validation of genetic findings, as this will likely 
require the assessment of additional biospecimens, 
including blood, skin fibroblasts, urine, or any other 
tissues that might be of interest for investigating the role 
of genetic variants. Furthermore, the patients’ families 
may help to recruit additional family members, including 
remote members who share very recent family history, 
for further genetic research, and this might help to 
separate truly disease causal variants from private but 
neutral variants in the family.
This idea can be extended to the concept of ‘clan 
genomics’ [125,126], which posits that there are unique 
combinations of rare variants in recent family lineages, 
playing a causative role in disease. In other words, 
recently arisen rare variants shared by a clan are more 
likely to be disease causal, compared with older common 
variants shared by a population or ethnicity group, 
particularly as such variants are too new to have been 
culled by natural selection. Therefore, for a specific 
patient, it is more important to consider the recent 
‘genetic history’ of the patient’s extended pedigree or 
clan, rather than their overall ethnic background. 
Genome sequencing on clans of subjects with elevated 
disease risks, such as on the Micronesian island of Kosrae 
[128] and Old Order Amish pedigree [129], may offer 
more important biological insights for identifying major-
effect disease genes and variants.
Conclusions
We have reviewed here the explosive growth of exome 
and genome sequencing, highlighting the progress and 
challenges of applying these technologies to find and 
catalog disease mutations in genomic medicine settings. 
At some point, we will reach a tipping point in which it 
will be more cost-effective to sequence a whole genome 
rather than a collection of candidate genes or even large 
candidate gene panels or exomes. With the ongoing 
efforts to further reduce the cost of sequencing and 
improve the quality and bioinformatic analysis of sequen-
cing data, the challenge in proving genetic causality will 
become more salient. In addition to improved bio infor-
matic and experimental approaches, this can be facili-
tated by a ‘networking of science’ model that requires 
collaborative efforts, and also by focusing on families in 
large pedigrees or the ‘clan genomics’ of subjects sharing 
recent genetic history. Forging strong ties with and 
among families will also enable access to other tissues to 
study newly discovered loci with many emerging tech-
nologies. As we enter this new period of individualized 
medicine [130], we expect that consumer-driven and 
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consumer-oriented efforts will allow translation of the 
human genome project directly back to each individual.
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